Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F10%3A%230000612" target="_blank" >RIV/00027162:_____/10:#0000612 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect

Popis výsledku v původním jazyce

Paclitaxel (PTX) is approved for the treatment of ovarian and breast cancer. The commercially preparation of PTX is associated with hypersensitivity reactions. The developed liposomal PTX formulations are troubled with low PTX encapsulation capacity (maximal content, 3 mol%) and accompanied by PTX crystallisation. Stable lyophilised preparation of PTX (7 mol%) encapsulated in the liposomes composed of SOPC/POPG/MOPC lipids (molar ratio, 60:20:20) doped with 5 mol% vitamin E had the size of 180-190 nm with zeta-potential of -31 mV. Sucrose (lipid/sugar molar ratio, 1:5-10) was found to preserve physical stability of PTX liposomes. This liposomal formulation did not show any evidence of toxicity in C57BL/6 mice treated with the highest doses of PTX (100mg/kg as a single dose and 150 mg/kg as a cumulative dose applied in 3 equivalent doses in 48-h intervals). A dose-dependent anticancer effect was found in both hollow fibre implants and syngenic B16F10 melanoma mouse tumour models.

Název v anglickém jazyce

Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect

Popis výsledku anglicky

Paclitaxel (PTX) is approved for the treatment of ovarian and breast cancer. The commercially preparation of PTX is associated with hypersensitivity reactions. The developed liposomal PTX formulations are troubled with low PTX encapsulation capacity (maximal content, 3 mol%) and accompanied by PTX crystallisation. Stable lyophilised preparation of PTX (7 mol%) encapsulated in the liposomes composed of SOPC/POPG/MOPC lipids (molar ratio, 60:20:20) doped with 5 mol% vitamin E had the size of 180-190 nm with zeta-potential of -31 mV. Sucrose (lipid/sugar molar ratio, 1:5-10) was found to preserve physical stability of PTX liposomes. This liposomal formulation did not show any evidence of toxicity in C57BL/6 mice treated with the highest doses of PTX (100mg/kg as a single dose and 150 mg/kg as a cumulative dose applied in 3 equivalent doses in 48-h intervals). A dose-dependent anticancer effect was found in both hollow fibre implants and syngenic B16F10 melanoma mouse tumour models.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Pharmaceutical Sciences

ISSN

0022-3549

e-ISSN

—

Svazek periodika

99

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000277132500009

EID výsledku v databázi Scopus

—